Ultra-precision nano-sensor could detect iron disorders

April 28, 2020

Chronic iron imbalances - having either too little or too much iron in the blood - can result in medical conditions ranging from anaemia and haemochromatosis through to more severe diseases, such as cancer, Parkinson's Disease and Alzheimer's Disease.

Haemochromatosis is one of Australia's most common hereditary diseases and the Australian Bureau of Statistics estimates approximately 780,000 people live with anaemia.

School of Biomedical Engineering PhD candidate and Sydney Nano Institute student ambassador, Pooria Lesani, who is undertaking his studies under the supervision of Professor Hala Zreiqat and Dr Zufu Lu, has developed a multipurpose nanoscale bio-probe that allows researchers to precisely monitor iron disorders in cells, tissue, and body fluids as small as 1/1000th of a millimolar[1].

The test is more sensitive and specific than blood testing currently used to detect iron disorders, which begin at very low, cellular level concentrations.

Using novel carbon-based fluorescent bio-nanoprobe technology, the test, which involves non-invasive subcutaneous or intravenous injections, allows for a more accurate disease diagnosis before the onset of symptoms, potentially allowing for the early treatment and prevention of more serious diseases.

"More than 30% of the world's population lives with an iron imbalance, which over time can lead to certain forms of cancer, as well Parkinson's Disease and Alzheimer's Disease," said Mr Lesani from the Tissue Engineering and Biomaterials Research Unit and the ARC Centre for Innovative BioEngineering.

"Current testing methods can be complex and time consuming. To counter this, and to enable the early detection of serious diseases, we have developed a hyper-sensitive and cost-efficient skin testing technique for detecting iron in the body's cells and tissue.

"Our most recent testing demonstrated a rapid detection of free iron ions with remarkably high sensitivity. Iron could be detected at concentrations in the parts per billion range, a rate ten times smaller than previous nano-probes.

"Our sensor is multifunctional and could be applied to deep-tissue imaging, involving a small probe that can visualise structure of complex biological tissues and synthetic scaffolds."

Tested on pig skin, the nanoprobe outperformed current techniques for deep tissue imaging, and rapidly penetrated biological tissue to depths of 280 micrometres and remained detectable at depths of up to 3,000 micrometres - about three millimetres - in synthetic tissue.

The team aims to test the nanoprobe in larger animal models, as well as investigate other ways in which it can be used to determine the structure of complex biological tissues.

We hope to integrate the nanoprobe into a "lab-on-a-chip" sensing system - a portable, diagnostic blood testing tool which could allow clinicians to remotely monitor their patients' health.

"Lab-on-a-chip systems are relatively simple to operate and require only small blood volume samples from the patient to gain an accurate insight of potential ferric ion disorders in the body, assisting early intervention and prevention of disease," he said.

The nano-sensors can also be made from agricultural and petrochemical waste products, allowing for low-cost, sustainable manufacturing.
-end-
DISCLOSURE:

The authors acknowledge funding from The Australian Research Council, The National Health and Medical Council and The Australian Centre for Microscopy and Microanalysis.

1. Refers to the number of moles of iron per litre of blood.

University of Sydney

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.